Myokardia Stock Price, News & Analysis (NASDAQ:MYOK)

$56.75 -0.50 (-0.87 %)
(As of 02/25/2018 04:00 PM ET)
Previous Close$56.75
Today's Range$55.60 - $58.49
52-Week Range$10.80 - $59.40
Volume304,713 shs
Average Volume255,582 shs
Market Capitalization$2.03 billion
P/E Ratio-74.67
Dividend YieldN/A
Beta4

About Myokardia (NASDAQ:MYOK)

Myokardia logoMyoKardia, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics. The Company has used its precision medicine platform to generate an initial pipeline of over four therapeutic programs for the chronic treatment of two forms of heritable cardiomyopathy-hypertrophic cardiomyopathy (HCM), and dilated cardiomyopathy (DCM). Additionally, the Company has three preclinical programs, HCM-2, DCM-2 and LUS-1. Its lead product candidate, MYK-461, is an orally-administered small molecule designed to reduce excessive cardiac muscle contractility leading to HCM.

Receive MYOK News and Ratings via Email

Sign-up to receive the latest news and ratings for MYOK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MYOK
CUSIPN/A
Phone650-741-0900

Debt

Debt-to-Equity RatioN/A
Current Ratio7.07%
Quick Ratio7.07%

Price-To-Earnings

Trailing P/E Ratio-74.6700701306562
Forward P/E Ratio-35.03
P/E GrowthN/A

Sales & Book Value

Annual Sales$39.20 million
Price / Sales51.74
Cash FlowN/A
Price / CashN/A
Book Value$4.63 per share
Price / Book12.26

Profitability

Trailing EPS($0.76)
Net Income$-13,150,000.00
Net Margins-53.49%
Return on Equity-14.92%
Return on Assets-11.53%

Miscellaneous

Employees78
Outstanding Shares35,740,000

Myokardia (NASDAQ:MYOK) Frequently Asked Questions

What is Myokardia's stock symbol?

Myokardia trades on the NASDAQ under the ticker symbol "MYOK."

How were Myokardia's earnings last quarter?

Myokardia Inc (NASDAQ:MYOK) posted its quarterly earnings results on Thursday, November, 2nd. The biotechnology company reported ($0.42) EPS for the quarter, meeting the consensus estimate of ($0.42). The biotechnology company earned $5.63 million during the quarter, compared to analysts' expectations of $6.10 million. Myokardia had a negative return on equity of 14.92% and a negative net margin of 53.49%. The company's quarterly revenue was up 58.6% compared to the same quarter last year. During the same period last year, the firm earned ($0.35) EPS. View Myokardia's Earnings History.

When will Myokardia make its next earnings announcement?

Myokardia is scheduled to release their next quarterly earnings announcement on Monday, March, 12th 2018. View Earnings Estimates for Myokardia.

Where is Myokardia's stock going? Where will Myokardia's stock price be in 2018?

6 brokers have issued 12 month price targets for Myokardia's shares. Their predictions range from $48.00 to $65.00. On average, they anticipate Myokardia's stock price to reach $55.67 in the next year. View Analyst Ratings for Myokardia.

Who are some of Myokardia's key competitors?

Who are Myokardia's key executives?

Myokardia's management team includes the folowing people:

  • Tassos Anastasios Gianakakos, President, Chief Executive Officer, Director (Age 44)
  • June Lee M.D., Chief Operating Officer (Age 51)
  • Jake Bauer, Senior Vice President - Finance and Corporate Development (Age 38)
  • Joseph Lambing Ph.D., Senior Vice President - Nonclinical and Pharmaceutical Development (Age 54)
  • Robert Scott McDowell Ph.D., Senior Vice President - Drug Discovery (Age 59)
  • Marc Semigran M.D., Chief Medical Officer (Age 60)
  • Mark L. Perry J.D., Interim Non-Executive Chairman of the Board, Lead Independent Director (Age 61)
  • Kevin P. Starr, Director (Age 54)
  • Sunil Agarwal M.D., Independent Director (Age 47)
  • Mary B. Cranston, Independent Director (Age 69)

Who owns Myokardia stock?

Myokardia's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (5.37%), Farallon Capital Management LLC (2.42%), Perceptive Advisors LLC (1.99%), Millennium Management LLC (1.37%), Wells Fargo & Company MN (1.00%) and Fernwood Investment Management LLC (0.74%). Company insiders that own Myokardia stock include Anastasios Gianakakos, Jake Bauer, Joseph Lambing, Kevin P Starr, Rock Ventures Ii LP Third, Sanofi and Wendy L Yarno. View Institutional Ownership Trends for Myokardia.

Who sold Myokardia stock? Who is selling Myokardia stock?

Myokardia's stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Two Sigma Investments LP, Wells Fargo & Company MN, EAM Investors LLC, Deutsche Bank AG, Bank of New York Mellon Corp, Bessemer Group Inc. and Essex Investment Management Co. LLC. Company insiders that have sold Myokardia company stock in the last year include Anastasios Gianakakos, Jake Bauer, Joseph Lambing, Kevin P Starr and Rock Ventures Ii LP Third. View Insider Buying and Selling for Myokardia.

Who bought Myokardia stock? Who is buying Myokardia stock?

Myokardia's stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Millennium Management LLC, Farallon Capital Management LLC, Perceptive Advisors LLC, Trustees of Princeton University, Hamilton Lane Advisors LLC, Eversept Partners LLC and Iguana Healthcare Management LLC. Company insiders that have bought Myokardia stock in the last two years include Sanofi and Wendy L Yarno. View Insider Buying and Selling for Myokardia.

How do I buy Myokardia stock?

Shares of Myokardia can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Myokardia's stock price today?

One share of Myokardia stock can currently be purchased for approximately $56.75.

How big of a company is Myokardia?

Myokardia has a market capitalization of $2.03 billion and generates $39.20 million in revenue each year. The biotechnology company earns $-13,150,000.00 in net income (profit) each year or ($0.76) on an earnings per share basis. Myokardia employs 78 workers across the globe.

How can I contact Myokardia?

Myokardia's mailing address is 333 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-741-0900 or via email at [email protected]


MarketBeat Community Rating for Myokardia (MYOK)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  115 (Vote Outperform)
Underperform Votes:  113 (Vote Underperform)
Total Votes:  228
MarketBeat's community ratings are surveys of what our community members think about Myokardia and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Myokardia (NASDAQ:MYOK) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $55.67$55.67$55.00$48.25
Price Target Upside: 5.83% upside5.83% upside13.75% upside19.50% upside

Myokardia (NASDAQ:MYOK) Consensus Price Target History

Price Target History for Myokardia (NASDAQ:MYOK)

Myokardia (NASDAQ:MYOK) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/18/2018Credit Suisse GroupReiterated RatingOutperform -> Outperform$60.00LowView Rating Details
12/12/2017JPMorgan Chase & Co.Initiated CoverageOverweight -> Overweight$54.00MediumView Rating Details
9/20/2017WedbushReiterated RatingOutperform$51.00HighView Rating Details
8/21/2017BMO Capital MarketsReiterated RatingOutperform$45.00 -> $65.00HighView Rating Details
8/7/2017CowenBoost Price TargetOutperform$28.00 -> $56.00HighView Rating Details
8/7/2017Wells Fargo & CoReiterated RatingOutperform$31.00 -> $48.00HighView Rating Details
(Data available from 2/25/2016 forward)

Earnings

Myokardia (NASDAQ:MYOK) Earnings History and Estimates Chart

Earnings by Quarter for Myokardia (NASDAQ:MYOK)

Myokardia (NASDAQ MYOK) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/12/2018($0.41)N/AView Earnings Details
11/2/2017Q3 2017($0.42)($0.42)$6.10 million$5.63 millionViewN/AView Earnings Details
8/7/2017Q2 2017($0.37)($0.41)$6.73 million$5.60 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.36)($0.37)$7.00 million$5.60 millionViewListenView Earnings Details
3/13/2017Q4 2016($0.18)$0.44$3.55 million$28.60 millionViewN/AView Earnings Details
11/7/2016Q316($0.07)($0.35)$4.83 million$3.55 millionViewN/AView Earnings Details
8/9/2016Q216($0.33)($0.37)$3.55 million$3.55 millionViewN/AView Earnings Details
5/12/2016Q1($0.53)($0.32)$3.55 million$3.55 millionViewN/AView Earnings Details
3/18/2016Q4($0.68)($0.48)$3.55 million$3.55 millionViewN/AView Earnings Details
11/18/2015Q3 2015($2.78)$3.55 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Myokardia (NASDAQ:MYOK) Earnings Estimates

2018 EPS Consensus Estimate: ($1.74)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.41)($0.41)($0.41)
Q2 20181($0.43)($0.43)($0.43)
Q3 20181($0.44)($0.44)($0.44)
Q4 20181($0.46)($0.46)($0.46)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Myokardia (NASDAQ:MYOK)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Myokardia (NASDAQ MYOK) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 33.40%
Institutional Ownership Percentage: 78.38%
Insider Trades by Quarter for Myokardia (NASDAQ:MYOK)
Institutional Ownership by Quarter for Myokardia (NASDAQ:MYOK)

Myokardia (NASDAQ MYOK) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/5/2018Anastasios GianakakosInsiderSell3,000$51.05$153,150.0077,390View SEC Filing  
1/12/2018Joseph LambingInsiderSell5,000$50.00$250,000.0095,846View SEC Filing  
1/9/2018Jake BauerInsiderSell5,000$45.00$225,000.0056,777View SEC Filing  
1/4/2018Anastasios GianakakosInsiderSell3,000$41.70$125,100.00512,117View SEC Filing  
1/3/2018Kevin P StarrDirectorSell816,326$42.00$34,285,692.00View SEC Filing  
1/2/2018Jake BauerInsiderSell5,000$42.89$214,450.0062,877View SEC Filing  
12/21/2017Anastasios GianakakosInsiderSell3,000$41.09$123,270.00512,117View SEC Filing  
11/6/2017Anastasios GianakakosCEOSell4,300$40.23$172,989.00513,417View SEC Filing  
10/4/2017Anastasios GianakakosInsiderSell4,300$40.86$175,698.00View SEC Filing  
10/3/2017Kevin P StarrDirectorSell75,313$40.28$3,033,607.64View SEC Filing  
9/26/2017Kevin P StarrDirectorSell601,400$43.00$25,860,200.00View SEC Filing  
9/26/2017Rock Ventures Ii L.P. ThirdMajor ShareholderSell400,000$43.00$17,200,000.00View SEC Filing  
9/25/2017Rock Ventures Ii L.P. ThirdMajor ShareholderSell201,400$43.00$8,660,200.00View SEC Filing  
9/11/2017Rock Ventures Ii L.P. ThirdMajor ShareholderSell221,250$41.30$9,137,625.00View SEC Filing  
9/8/2017Kevin P StarrDirectorSell201,250$41.01$8,253,262.50View SEC Filing  
9/5/2017Anastasios GianakakosInsiderSell4,300$43.02$184,986.00512,463View SEC Filing  
8/22/2017Joseph LambingInsiderSell5,000$45.00$225,000.0099,718View SEC Filing  
8/15/2017Joseph LambingInsiderSell5,000$40.00$200,000.00104,718View SEC Filing  
8/14/2017SanofiMajor ShareholderBuy350,000$35.50$12,425,000.00View SEC Filing  
8/14/2017Wendy L YarnoDirectorBuy1,408$35.50$49,984.001,408View SEC Filing  
8/8/2017Joseph LambingInsiderSell15,000$30.00$450,000.00119,718View SEC Filing  
8/7/2017Jake BauerInsiderSell15,000$28.33$424,950.0075,545View SEC Filing  
8/4/2017Anastasios GianakakosCEOSell4,300$16.62$71,466.00512,463View SEC Filing  
7/25/2017Anastasios GianakakosInsiderSell32,988$15.00$494,820.00541,151View SEC Filing  
3/20/2017Anastasios GianakakosCEOSell1,412$15.00$21,180.00509,454View SEC Filing  
3/20/2017Jake BauerInsiderSell667$15.00$10,005.0083,900View SEC Filing  
10/3/2016SanofiMajor ShareholderBuy450,000$15.00$6,750,000.00View SEC Filing  
11/3/2015Anastasios GianakakosCEOBuy1,350$10.00$13,500.00482,165View SEC Filing  
11/3/2015Jonathan C FoxInsiderBuy3,000$10.00$30,000.00239,190View SEC Filing  
11/3/2015Mark L PerryDirectorBuy5,000$10.00$50,000.0025,408View SEC Filing  
11/3/2015SanofiMajor ShareholderBuy900,000$10.00$9,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Myokardia (NASDAQ MYOK) News Headlines

Source:
DateHeadline
Myokardia (MYOK) Rating Increased to Buy at BidaskClubMyokardia (MYOK) Rating Increased to Buy at BidaskClub
www.americanbankingnews.com - February 17 at 1:24 PM
BRIEF-Myokardia Begins Patient Dosing In Phase 1B Clinical Study Of Myk-491BRIEF-Myokardia Begins Patient Dosing In Phase 1B Clinical Study Of Myk-491
www.reuters.com - February 15 at 8:13 AM
MyoKardia to Present at the RBC Capital Markets’ 2018 Healthcare ConferenceMyoKardia to Present at the RBC Capital Markets’ 2018 Healthcare Conference
finance.yahoo.com - February 14 at 5:11 PM
MyoKardia Begins Patient Dosing in Phase 1b Clinical Study of MYK-491 in Dilated Cardiomyopathy PatientsMyoKardia Begins Patient Dosing in Phase 1b Clinical Study of MYK-491 in Dilated Cardiomyopathy Patients
finance.yahoo.com - February 14 at 9:35 AM
Zacks: Analysts Anticipate Myokardia Inc (MYOK) Will Announce Quarterly Sales of $5.63 MillionZacks: Analysts Anticipate Myokardia Inc (MYOK) Will Announce Quarterly Sales of $5.63 Million
www.americanbankingnews.com - February 9 at 3:50 AM
Anastasios Gianakakos Sells 3,000 Shares of Myokardia Inc (MYOK) StockAnastasios Gianakakos Sells 3,000 Shares of Myokardia Inc (MYOK) Stock
www.americanbankingnews.com - February 8 at 12:46 AM
Myokardia (MYOK) Rating Increased to Hold at ValuEngineMyokardia (MYOK) Rating Increased to Hold at ValuEngine
www.americanbankingnews.com - February 4 at 9:14 PM
Myokardia Inc (MYOK) Given Consensus Rating of "Buy" by BrokeragesMyokardia Inc (MYOK) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - February 3 at 5:32 PM
MyoKardia Announces Appointment of Cynthia Ladd as General CounselMyoKardia Announces Appointment of Cynthia Ladd as General Counsel
finance.yahoo.com - January 27 at 9:58 AM
Myokardia Inc (MYOK) Expected to Announce Quarterly Sales of $5.63 MillionMyokardia Inc (MYOK) Expected to Announce Quarterly Sales of $5.63 Million
www.americanbankingnews.com - January 23 at 6:50 AM
Growing Biotech Hires New GCGrowing Biotech Hires New GC
finance.yahoo.com - January 22 at 4:15 PM
Myokardias (MYOK) Outperform Rating Reaffirmed at Credit Suisse GroupMyokardia's (MYOK) Outperform Rating Reaffirmed at Credit Suisse Group
www.americanbankingnews.com - January 21 at 6:22 PM
Zacks: Analysts Expect Myokardia Inc (MYOK) Will Announce Earnings of -$0.40 Per ShareZacks: Analysts Expect Myokardia Inc (MYOK) Will Announce Earnings of -$0.40 Per Share
www.americanbankingnews.com - January 21 at 1:08 PM
Beigene (BGNE) and Myokardia (MYOK) Critical ReviewBeigene (BGNE) and Myokardia (MYOK) Critical Review
www.americanbankingnews.com - January 19 at 1:08 AM
Joseph Lambing Sells 5,000 Shares of Myokardia Inc (MYOK) StockJoseph Lambing Sells 5,000 Shares of Myokardia Inc (MYOK) Stock
www.americanbankingnews.com - January 16 at 9:50 PM
Reviewing Myokardia (MYOK) and Aurinia Pharmaceuticals (AUPH)Reviewing Myokardia (MYOK) and Aurinia Pharmaceuticals (AUPH)
www.americanbankingnews.com - January 13 at 3:06 PM
Myokardia Inc (MYOK) Insider Jake Bauer Sells 5,000 SharesMyokardia Inc (MYOK) Insider Jake Bauer Sells 5,000 Shares
www.americanbankingnews.com - January 10 at 8:00 PM
Myokardia Inc (MYOK) Receives Consensus Rating of "Hold" from AnalystsMyokardia Inc (MYOK) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - January 9 at 7:08 PM
Zacks: Analysts Expect Myokardia Inc (MYOK) Will Post Quarterly Sales of $5.63 MillionZacks: Analysts Expect Myokardia Inc (MYOK) Will Post Quarterly Sales of $5.63 Million
www.americanbankingnews.com - January 6 at 3:38 AM
Myokardia Inc (MYOK) Insider Sells $125,100.00 in StockMyokardia Inc (MYOK) Insider Sells $125,100.00 in Stock
www.americanbankingnews.com - January 5 at 6:50 PM
Myokardia Inc (MYOK) Director Kevin P. Starr Sells 816,326 SharesMyokardia Inc (MYOK) Director Kevin P. Starr Sells 816,326 Shares
www.americanbankingnews.com - January 5 at 6:16 PM
 Brokerages Anticipate Myokardia Inc (MYOK) to Post -$0.40 Earnings Per Share Brokerages Anticipate Myokardia Inc (MYOK) to Post -$0.40 Earnings Per Share
www.americanbankingnews.com - January 4 at 5:32 PM
Jake Bauer Sells 5,000 Shares of Myokardia Inc (MYOK) StockJake Bauer Sells 5,000 Shares of Myokardia Inc (MYOK) Stock
www.americanbankingnews.com - January 3 at 9:54 PM
MyoKardia to Present at 36th Annual J.P. Morgan Healthcare ConferenceMyoKardia to Present at 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 3 at 5:28 PM
Insider Selling: Myokardia Inc (MYOK) Insider Sells 3,000 Shares of StockInsider Selling: Myokardia Inc (MYOK) Insider Sells 3,000 Shares of Stock
www.americanbankingnews.com - December 26 at 5:45 PM
ETFs with exposure to MyoKardia, Inc. : December 26, 2017ETFs with exposure to MyoKardia, Inc. : December 26, 2017
finance.yahoo.com - December 26 at 2:41 PM
Myokardia (MYOK) Lifted to "Hold" at BidaskClubMyokardia (MYOK) Lifted to "Hold" at BidaskClub
www.americanbankingnews.com - December 26 at 6:04 AM
MyoKardia, Inc. :MYOK-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017MyoKardia, Inc. :MYOK-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017
finance.yahoo.com - December 25 at 3:17 PM
Myokardia (MYOK) Cut to Sell at BidaskClubMyokardia (MYOK) Cut to Sell at BidaskClub
www.americanbankingnews.com - December 24 at 8:05 AM
Head to Head Contrast: Myokardia (MYOK) & PTC Therapeutics (PTCT)Head to Head Contrast: Myokardia (MYOK) & PTC Therapeutics (PTCT)
www.americanbankingnews.com - December 24 at 1:31 AM
 Analysts Expect Myokardia Inc (MYOK) Will Post Quarterly Sales of $5.63 Million Analysts Expect Myokardia Inc (MYOK) Will Post Quarterly Sales of $5.63 Million
www.americanbankingnews.com - December 21 at 2:02 PM
Comparing Threshold Pharmaceuticals (MTEM) & Myokardia (MYOK)Comparing Threshold Pharmaceuticals (MTEM) & Myokardia (MYOK)
www.americanbankingnews.com - December 21 at 11:26 AM
 Brokerages Anticipate Myokardia Inc (MYOK) Will Post Earnings of -$0.40 Per Share Brokerages Anticipate Myokardia Inc (MYOK) Will Post Earnings of -$0.40 Per Share
www.americanbankingnews.com - December 19 at 3:14 AM
Myokardia Inc (MYOK) Given Consensus Recommendation of "Buy" by BrokeragesMyokardia Inc (MYOK) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - December 15 at 5:26 PM
Myokardia (MYOK) Lifted to Hold at BidaskClubMyokardia (MYOK) Lifted to Hold at BidaskClub
www.americanbankingnews.com - December 12 at 8:00 PM
Myokardia (MYOK) Research Coverage Started at J P Morgan Chase & CoMyokardia (MYOK) Research Coverage Started at J P Morgan Chase & Co
www.americanbankingnews.com - December 12 at 9:04 AM
Head-To-Head Analysis: Myokardia (MYOK) versus Its PeersHead-To-Head Analysis: Myokardia (MYOK) versus Its Peers
www.americanbankingnews.com - December 11 at 1:36 PM
MyoKardia, Inc. breached its 50 day moving average in a Bullish Manner : MYOK-US : December 11, 2017MyoKardia, Inc. breached its 50 day moving average in a Bullish Manner : MYOK-US : December 11, 2017
finance.yahoo.com - December 11 at 10:08 AM
MyoKardia (MYOK) Rating Lowered to Sell at ValuEngineMyoKardia (MYOK) Rating Lowered to Sell at ValuEngine
www.americanbankingnews.com - December 3 at 12:40 AM
MyoKardia, Inc. (MYOK) Given Consensus Rating of "Buy" by BrokeragesMyoKardia, Inc. (MYOK) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - November 20 at 5:44 PM
Preclinical Studies with MyoKardia’s Mavacamten Demonstrate Evidence of Reduced Contractility and Improved Left Ventricular CompliancePreclinical Studies with MyoKardia’s Mavacamten Demonstrate Evidence of Reduced Contractility and Improved Left Ventricular Compliance
finance.yahoo.com - November 18 at 6:22 AM
MyoKardia Presents Data from Study of Machine Learning Algorithm Intended to Identify Obstructive Hypertrophic Cardiomyopathy Using a Wearable BiosensorMyoKardia Presents Data from Study of Machine Learning Algorithm Intended to Identify Obstructive Hypertrophic Cardiomyopathy Using a Wearable Biosensor
finance.yahoo.com - November 14 at 3:20 AM
Myokardia Inc (MYOK) Q3:17 Update At First GlanceMyokardia Inc (MYOK) Q3:17 Update At First Glance
finance.yahoo.com - November 9 at 6:46 AM
MyoKardia, Inc. – Value Analysis (NASDAQ:MYOK) : November 8, 2017MyoKardia, Inc. – Value Analysis (NASDAQ:MYOK) : November 8, 2017
finance.yahoo.com - November 9 at 6:46 AM
MyoKardia, Inc. (MYOK) CEO Anastasios Gianakakos Sells 4,300 SharesMyoKardia, Inc. (MYOK) CEO Anastasios Gianakakos Sells 4,300 Shares
www.americanbankingnews.com - November 8 at 7:38 PM
TheStreet Downgrades MyoKardia, Inc. (MYOK) to D+TheStreet Downgrades MyoKardia, Inc. (MYOK) to D+
www.americanbankingnews.com - November 7 at 9:36 AM
MyoKardia, Inc. breached its 50 day moving average in a Bullish Manner : MYOK-US : November 6, 2017MyoKardia, Inc. breached its 50 day moving average in a Bullish Manner : MYOK-US : November 6, 2017
finance.yahoo.com - November 7 at 7:14 AM
Reviewing Viking Therapeutics (VKTX) & MyoKardia (MYOK)Reviewing Viking Therapeutics (VKTX) & MyoKardia (MYOK)
www.americanbankingnews.com - November 7 at 3:28 AM
Edited Transcript of MYOK earnings conference call or presentation 2-Nov-17 8:30pm GMTEdited Transcript of MYOK earnings conference call or presentation 2-Nov-17 8:30pm GMT
finance.yahoo.com - November 6 at 3:48 AM
MyoKardia Reports Third Quarter 2017 Financial Results and Operational ProgressMyoKardia Reports Third Quarter 2017 Financial Results and Operational Progress
finance.yahoo.com - November 4 at 6:53 AM

SEC Filings

Myokardia (NASDAQ:MYOK) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Myokardia (NASDAQ:MYOK) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Myokardia (NASDAQ MYOK) Stock Chart for Sunday, February, 25, 2018

Loading chart…

This page was last updated on 2/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.